Clinical trial NCT05329844: The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.
Official title: Randomized, Open Label, Two-sequence, Two-treatment, Two-period, Crossover, Single Dose Bioequivalence Study of Vildagliptin Tablets 50 mg of AET Laboratories Pvt. Ltd., India With Galvus 50 mg Tablets of Novartis Europharm Ltd., United Kingdom in Normal Healthy, Adult, Male Human Subjects Under Fasting Conditions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: Alfred E. Tiefenbacher (GmbH & Co. KG)
Sponsor class: INDUSTRY
First posted: 2022-04-15
Enrollment: 66
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: To evaluate and compare the relative bioavailability and therefore the bioequivalence of Vildagliptin Tablets 50 mg of AET Laboratories Private Limited, India, with GALVUS® 50 mg Tablets of Novartis Europharm Limited, United Kingdom, in normal, healthy, adult, male human subjects under fasting conditions and to evaluate the safety and tolerability of Vildagliptin Tablets 50 mg in normal, healthy, adult, male human subjects under fasting conditions.


Eligibility criteria: Inclusion Criteria:

1. Male subjects aged between 18 and 45 years (both inclusive).
2. Subjects' weight within the normal range according to normal values for the Body Mass Index (18.5 to 30 kg/m2) with minimum of 50 kg weight.
3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable normal range.
4. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
5. Subjects having clinically acceptable chest X-Ray.
6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
7. Subjects having negative alcohol breath test.
8. Subjects willing to adhere to the protocol requirements and to provide written informed consent.
9. No history or presence of smoking.
10. No history or presence of alcoholism and drug of abuse.

Exclusion Criteria:

1. Hypersensitivity to Vildagliptin or related class of drugs.
2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
4. History or presence of asthma, urticaria or other significant allergic reactions.
5. History or presence of significant gastric and/or duodenal ulceration.
6. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
7. History or presence of cancer.
8. Difficulty with donating blood.
9. Difficulty in swallowing solids like tablets or capsules.
10. Use of any prescribed or OTC medication during last two weeks prior to Dosing in Period 01.
11. Major illness during 3 months before screening.
12. Participation in a drug research study within past 3 months.
13. Donation of blood in the past 3 months before screening.
14. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
15. History or presence of significant easy bruising or bleeding.
16. History or presence of significant recent trauma.
17. Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.

Primary outcomes:
measure: Cmax of Vildagliptin for the test and reference products
timeFrame: up to 24 hours
measure: AUC0-t of Vildagliptin for the test and the reference products
timeFrame: up to 24 hours
Secondary outcomes:
measure: AUC0-∞ of Vildagliptin for the test and the reference products
timeFrame: up to 24 hours
measure: Tmax of Vildagliptin for the test and the reference products
timeFrame: up to 24 hours
measure: T1/2 of Vildagliptin for the test and the reference products
timeFrame: up to 24 hours
measure: Kel of Vildagliptin for the test and the reference products
timeFrame: up to 24 hours
measure: Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol
timeFrame: through study completion, an average of 1 month
Other outcomes:
Locations:
Study officials:
References: